Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1–infected Adolescents-Reference-Cited by-同舟云学术

Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1–infected Adolescents

Published:2014-09 Issue:9 Volume:33 Page:940-945
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Flynn Patricia,Komar Svitlana,Blanche Stephane,Giaquinto Carlo,Noguera-Julian Antoni,Welch Steven,Lathouwers Erkki,Van de Casteele Tom,Kakuda Thomas N.,Opsomer Magda

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology, and Child Health

Reference21 articles.

1. POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.;Clotet;Lancet,2007

2. TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.;Madruga;Lancet,2007

3. Pharmacokinetics, safety and efficacy of darunavirritonavir in treatment-experienced children and adolescents.;Blanche;AIDS,2009

4. Pharmacokinetics of darunavirritonavir and TMC125 alone and coadministered in HIV-negative volunteers.;Scholler-Gyure;Antivir Ther,2007

5. Tolerability and safety of HIV protease inhibitors in adults.;Sax;J Acquir Immune Defic Syndr,2004

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update;Current Drug Metabolism;2023-07

2. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies);The AAPS Journal;2021-06-07

3. The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years;Drug Safety;2020-12-24

4. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1;HIV Research & Clinical Practice;2020-11-01

5. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients;AIDS;2020-04-01